The FDA has approved Sanofi Pasteur's Fluzone Intradermal Quadrivalent vaccine for use in adults who are 18 to 64 years old. The vaccine offers protection against influenza A subtype viruses and type B viruses.
The European Commission has approved the use of Sanofi Pasteur's cervical cancer vaccine Gardasil in men and women for prevention of anal precancerous lesions and anal cancers caused by select oncogenic human papillomavirus types.
In a clinical trial involving 5,168 3- to 8-year-olds, researchers found that an inactivated quadrivalent flu vaccine yielded an overall effectiveness rate of 55% in preventing influenza A or B of any severity. The vaccine had an efficacy of about 70% in protecting children against moderate to severe flu and was linked to an 80% decline in lower respiratory tract infections, according to the study published in the New England Journal of Medicine.
The European Medicines Agency endorsed AstraZeneca's nasal spray quadrivalent influenza vaccine for European Commission approval. The vaccine could be released in the European market for the 2014-2015 flu season if it wins approval.
GlaxoSmithKline secured approval from the FDA to supply its influenza vaccine, Fluarix Quadrivalent, to CDC distribution centers and health care providers in the U.S. Fluarix was approved by the FDA last year to protect adults and children 3 and older against four strains of flu. The CDC ordered more than 4 million doses of the vaccine.